ARTV artivabio.com Final Profit

Corporate emblem and logo of artivabio.com (ARTV)

Business continuity risks for Artiva Biotherapeutics, Inc. (ARTV) are linked to the high cost of NK-cell production. This GURU.Markets chart, where the company's net income reaches -0.09, confirms a dependence on grants due to the absence of commercial products. Meanwhile, the allogeneic therapy scaling strategy is designed to reduce costs, making oncological care more accessible through the creation of universal cell-based drugs.

ARTV (Artiva) Net Profit history from 07/20/2024 to 11/01/2026

Analytical breakdowns and data insights for company artivabio.com (ARTV)

- stock value and consensus price forecast:
Market Price Artiva Biotherapeutics|ARTV - Price Target Chart
- market capitalization data:
Market Value Artiva Biotherapeutics, Inc.|ARTV - Real Price to Acquire Entire Company
- business book valuation details:
Accounting Value of a Share Artiva Biotherapeutics|ARTV - Book Capitalization|Market Cap to Net Assets Ratio artivabio.com|ARTV - Cumulative Company Assets
- debt and solvency information:
Total Debt to Capital Artiva Biotherapeutics, Inc.|ARTV - Long-Term Debt to Equity|Ratio of Short-Term Indebtedness to Capital Artiva Biotherapeutics|ARTV - Company Aggregate Debts|Debts to Book Value Artiva Biotherapeutics, Inc.|ARTV - Company Long-Term Debts|Company Short-Term Debts Artiva Biotherapeutics|Intermediate Coverage Ratio artivabio.com
- net income and valuation multiples indicators:
ARTV - Net Income
Fundamental valuation:ARTV Artiva
Manufactured product of Artiva Biotherapeutics Inc.

This indicator captures daily net income stripped of market noise, allowing investors to objectively assess the fundamental stability of the business regardless of stock quotes. By analyzing the operating profit of Artiva Biotherapeutics, Inc. (ARTV), one can track the cost efficiency of Artiva Biotherapeutics, Inc. (ARTV) regarding joint oncology research and the development of cell therapies in partnership with academic institutions.

Direct competitors

Company Net Income BeiGene Oncology (ONC)|Company Net Income Halozyme Therapeutics|RVMD: Final Profit|Net Income AAPG (Ascentage Pharma)|CGON (CG Oncology Inc) - Final Profit|Net Profit URGN (UroGen)|BCAX - Net Income|PSNL: Net Income|ERAS - Net Profit|Delcath Systems (DCTH) - Company Net Income|Y-mAbs Therapeutics Inc - Final Profit|AURA (Aura Bio) - Net Profit|Company Net Income Candel CADL|Net Profit ARAY|Net Profit sellaslifesciences.com (SLS)|Company Net Income Actuate Therapeutics ACTU|Final Profit CTOR|HURA: Net Income|Protara Tx - Profit After Payment of Taxes|FATE: Net Profit|WHWK - Net Financial Result|Net Income TCRX|Company Net Income CSBR|Net Profit XBIT|Net Profit cel-sci.com (CVM)|OS Therapies Incorporated - Net Income|Final Profit RADX|Adlai Nortye Limited - Net Profit|VERU: Company Net Income|TPST: Net Profit|XLO - Net Financial Result|Company Net Income Renovaro Biosciences|Company Net Income Mural Bio MURA|Net Income KAPA (Kairos Pharma Ltd)|Profit After Payment of Taxes OKUR|Net Profit GDTC (CytoMed Therapeutics Limited)|Final Profit CRIS|Apollomics Corp - Net Profit|Company Net Income tharimmune.com|advanbiomed.com (ADVB) - Company Net Income|Genprex Inc. - Final Profit|CLDI (Calidi Biotherapeutics Inc.) - Net Profit|Net Profit Sunshine Biopharma Inc.|Company Net Income Xenetic Biosciences (XBIO)|SLRX: Profit After Tax|Net Profit PPBT (Purple Biotech Ltd.)|American Oncology Network Inc (AONC) - Company Net Income|BGNE: Net Income|CKPT - Net Profit|ELEV (Elevation Oncology, Inc.) - Net Income|ICAD: Profit After Payment of Taxes|IKNA (Ikena Oncology Inc.) - Net Profit|Notable Labs Ltd (NTBL) - Net Financial Result|Net Profit VIRX|Net Income MorphoSys Corporation MOR|Company Net Income NAYA Biosciences NAYA|Net Financial Result ascentage.com (AAPGV)